RET fusion in papillary thyroid carcinoma (PTC) — ~5-10% sporadic, enriched in radiation-...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-RET-FUSION-THYROID-PAPILLARY |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-THYROID-PAPILLARY |
| Sources | SRC-CIVIC SRC-NCCN-CNS-2025 |
Actionability Facts
| Biomarker | BIO-RET |
|---|---|
| Variant | fusion (CCDC6-RET, NCOA4-RET, ELKS-RET et al.) — distinct from MTC mutations |
| Disease | DIS-THYROID-PAPILLARY |
| ESCAT tier | IB |
| Recommended combinations | selpercatinib monotherapy (RAI-refractory advanced disease), pralsetinib monotherapy |
| Contraindicated monotherapy | lenvatinib / sorafenib (reserve for RET-fusion-negative or post-RET-TKI failure) |
| Evidence summary | RET fusion in papillary thyroid carcinoma (PTC) — ~5-10% sporadic, enriched in radiation-induced PTC. Selpercatinib (LIBRETTO-001 PTC cohort, Wirth 2020 — ORR 79%) and pralsetinib (ARROW PTC cohort, ORR 89%) are FDA-approved for RAI-refractory advanced disease. Selective RET-TKIs are preferred over sorafenib / lenvatinib for RET-fusion-positive RAI-refractory disease. |
Notes
ESCAT IB. OncoKB Level 1. RAI ablation remains 1L for differentiated PTC; selective RET-TKIs are deployed in RAI-refractory progressive metastatic disease. Detection: RNA-NGS preferred. Source-gap: SRC-NCCN-THYROID-2025 placeholder; SRC-LIBRETTO001-DRILON-2020 / SRC-ARROW not yet ingested.
Used By
No reverse references found in the YAML corpus.